

RELEVANS OF DEVELOPMENT OF COMBINED ANTIDIABETIC PREPARATION

Marchenko M.V., Sushovoy D.E.

The National University of Pharmacy, Kharkiv, Ukraine

Profesor87@inbox.ru

Solving the problem of the treatment of diabetes mellitus (DM) type 2 and the associated metabolic syndrome (MS) is an important task of modern medicine and pharmacy

To date, there is no consensus about the root causes of MS: is this state caused by genetic or develop exclusively due to the action of environmental factors.

A number of researchers believe that the development of MS due to the existence of one or a group of genes which interact with each other, which can simultaneously stimulate the development of all its components. However, despite significant advances in genetics and molecular biology, the question of the influence of genetic factors on the risk of developing MS and features of the course are still poorly understood

Acuteness of the problem in the first place due to the prevalence of MS (up to 20% of the population and 70% among patients with type 2 diabetes), which is defined by WHO epidemiological in nature, and secondly - the limited range of medicines that affect the basic pathogenetic links of the disease, and namely the elimination of insulin resistance (IR). Furthermore, derivatives of dimetilbiguanid (metformin) and thiazolidinedione (rosiglitazone), which increase insulin sensitivity due to side effects have limited application and therefore cannot solve the problem.

Given the many manifestations of MS component, promising event pharmacotherapy of the disease is the use of combined antidiabetic drugs on the basis of metformin and rosiglitazone without or in combination with glibenclamide. However, such drugs have some inherent side effects of their active substances.

In view of the above, development of the combined antidiabetic is the actual drug with metformin and medical substance the original diacamph, which developed in pharmacy, is the actual.

Due to its low toxicity and spectrum of pharmacological properties of diacamph, his pharmaceutical composition with metformin may have certain advantages over precursors of drugs.